APLS— Apellis Pharmaceuticals, Inc.

$41.03-0.07%

NasdaqMaterialsPharmaceutical Preparations

1 insider sold $8K in the last 30 days — 6.9x above baseline

Sell Velocity Score

6.93x

Sell Rate (90d)

4.09 sh/day

Sell Baseline Rate

—

Unique Sellers (90d)

Price Chart

Loading…

Insider Transactions

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-02-11	2026-02-13	DeLong Mark Jeffrey	Chief Business & Strat Officer	Sale	368	$22.15	$8K	114.6K	View ↗

No recent congressional transactions.

Revenue

No data

Operating Income

No data

Net Income

No data

Free Cash Flow

$45.0M

+151.0% YoY

No annual data found.

Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price

Biogen completes $5.3B Apellis Pharmaceuticals acquisition

Biogen Completes Acquisition of Apellis Pharmaceuticals